JAK3 Tyrosine Kinase Inhibitors (Cytopia/Novartis)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameJAK3 Tyrosine Kinase Inhibitors (Cytopia/Novartis)

Drug Alias NameJAK Protein Tyrosine Kinase Inhibitors (Cytopia/Novartis)JAK3 tyrosine kinase inhibitors (Cytopia)JAK protein tyrosine kinase inhibitors (Cytopia)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors

TargetsTyrosine-protein kinase JAK3

Therapy Area/IndicationsRejection of organ transplantationAutoimmune DiseasesRespiratory Tract Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New ZealandSwitzerland

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesYM BioSciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNovartis Ag YM BioSciences Inc

Active IndicationsN/A

Inactive IndicationsRejection of organ transplantationAutoimmune DiseasesRespiratory Tract Infections

Other Information

ATC CodeN/A